xerient

Advanced Abdominal & Gastrointestinal Cancer Solutions

About

Vision

Focused on unmet needs in cancer treatment, particularly in abdominal/GI cancers through novel treatments and diagnostic technologies, and dramatically improve the survival of these patients

IP & Partners

Proprietary and licensed technology from MD Anderson Cancer Center, Stanford University, and Rice University

Technology

Treatment - Making radiotherapy available for pancreatic cancer patients by using protection prior to applying radiation

Diagnostic & Monitoring - Detecting pancreatic, colon, and stomach cancer cells by Implementing antibodies detecting newly discovered specific markers

A Technology Platform

Technology Platform applicable to treatments and diagnostics of other gastrointestinal tract cancers

The Problem

In Pancreatic Cancer

- **No Early Detection Methods**
- **Only 10-20% are surgical candidates** due to location of the tumor and its spread
- **Tumor is typically not controlled by chemotherapy**
- **Radiation therapy** can sometimes be used to approximate surgery
- **High radiotoxicity** to adjacent organs (specifically the duodenum)
- **no protection to the intestines** when delivering higher doses of targeted radiation for pancreatic tumors) makes effective radiation impractical

Xerient presents a novel approach that opens the door for the use of radiation in the treatment of pancreatic cancer patients

xerient

Our Therapeutic Solution

Based on revolutionary collaborative research between a leading-expert in Pancreatic Cancer Treatment – Dr. Cullen Taniguchi of MD Anderson Cancer Center and world reknowned chemist - Prof. James Tour of Rice University

Repurposing of FDA Approved Prodrug

Utilized for other applications and FDA-approved for intravenous (IV) administration

Oral Administration*

Administering to the patient **orally** dosed cytoprotective drug at a predetermined time prior to exposure to radiation

Organ Protection

The orally-dosed cytoprotective drug serve as **highly selective intestinal radioprotector**

Effective Radiation

Delivering the appropriate tumoricidal dose of radiation without inducing duodenal destruction

***Oral Administration of the drug is clinically safe**

xerient

Our Diagnostic Solution - XR10 & XR15 Monoclonal Antibody

- XR10 targets CD66c, an aggression molecule used by cancer cells for invasion and dissemination leading to metastasis
- The research and development work on XR10 have been conducted by industry and academia and supported by prestigious grant awards amounting for over $20M
- Major effort – developing XR10 as a drug. Open opportunity as a diagnostic and monitoring tool
- XR10 was tested in 150 human tissue samples where it demonstrated extremely high specificity (>90%)
- IP protects the biological, structural and attributes of the antibody and utilizing it alone and in connection to additional antibodies for enhanced results



xerient

THERAPEUTICS ROADMAP



DIAGNOSTICS ROADMAP

Licensing Agreement

Development work

Focused on converting the tissue results to the serum

Solidifying the IP

Testing in Patients' Serum

Internal work of testing the assays in high-end samples

Pre-Submission filing w/FDA

Extensive Clinical Studies

work following the pathway defined with FDA

Negotiation with CLIA labs

Finalizing the clinical studies

Defining reimbursement

FDA approval Diagnostic

Partnership for manufacturing and marketing

xerient

Conclusion

- **Targeting unmet needs** in the cancer space
- **Building the company on proven technologies** based on solid science and advanced research
- **Repurposing of FDA-approved drug** (not development of a new one), oral administration of the drug already proven clinically safe
- **Strong and experienced** management with support of industry leaders on BOD and SAB
- **Received** in August 2022 the very lucrative and **non-diluting CPRIT grant of $3M**
- **Funded by two leading seed stage VC,** committed to participate in follow on rounds
- **Initiating human studies in early 2023** for the therapeutic product, with potential regulatory approval of the diagnostic tool by 2024
- **Seeking additional $3M** to fund the company through **Phase IIa** and **complete** the diagnostic development ($3M secured from CPRIT (grant) in October 2022)

xerient

Advanced Abdominal &
gastrointestinal Cancer Solutions

Thank You.